Current insights into the role of HIF-PHD axis in renal anemia / 生理学报
Acta Physiologica Sinica
;
(6): 623-629, 2018.
Article
Dans Chinois
| WPRIM
| ID: wpr-777222
ABSTRACT
Renal anemia, mainly caused by the deficiencies of erythropoietin (EPO) and iron metabolism disorder, is one of the most common complications of chronic kidney disease. Hypoxia-inducible factor (HIF) is a class of transcription factors responsible for maintaining homeostasis during oxygen deprivation. In normoxia, HIF is degraded by prolyl hydroxylase (PHD). While under hypoxic conditions, the hydroxylation activity of PHD is inhibited, and the cellular concentration of HIF is elevated, resulting in an increase in endogenous EPO production and iron absorption. Therefore, this regulating pathway, also termed as the HIF-PHD axis, has become a promising therapeutic target of treating renal anemia. Several innovative drugs acting as selective HIF-PHD inhibitors have been successfully developed in the past years, and some of them are undergoing clinical trials. In this review, we will introduce the definition and regulatory mechanism of HIF-PHD axis, as well as current insights into its physiologic and therapeutic role in renal anemia.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Oxygène
/
Anatomopathologie
/
Facteur-1 induit par l'hypoxie
/
Prolyl hydroxylases
/
Anémie
/
Maladies du rein
/
Hypoxie
/
Métabolisme
Limites du sujet:
Humains
langue:
Chinois
Texte intégral:
Acta Physiologica Sinica
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS